Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of "Scratch Resistance," its new ...

A panelist discusses how real-world data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) ...

Held in partnership with HCPLive® and Dermatology Times®, RAD 2025 is designed to arm dermatologists and other health care ...

On Tuesday morning, Galderma launched its Scratch Resistance campaign to highlight one of the most difficult symptoms of ...

Dermatology providers reported strong impacts on the work and home life of patients with moderate to severe chronic hand eczema, a manifestation of atopic dermatitis.

2-3 While treatment options for atopic dermatitis are available, many patients remain frustrated and disappointed with the limitations of these options, with 87% of patients seeking freedom from ...

Aclaris Therapeutics, Inc.’s ACRS share price has surged by 6.72%, which has investors questioning if this is right time to sell.

The Revolutionizing Atopic Dermatitis (RAD) Conference 2025 takes place June 6–7 at the DoubleTree by Hilton Hotel Nashville Downtown, offering cutting-edge updates on the treatment and ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

Tralokinumab use in patients with head and neck atopic dermatitis was associated with sustained improvements with up to 4 years of treatment.